Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.
Vancouver, British Columbia-based Zymeworks also received an undisclosed upfront payment and an equity investment from Celgene to use its Azymetric platform for the discovery and development of multiple bi-specific antibody therapeutics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?